Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Interpace Diag Group (IDXG)

Interpace Diag Group (IDXG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,834
  • Shares Outstanding, K 4,037
  • Annual Sales, $ 24,080 K
  • Annual Income, $ -26,730 K
  • 60-Month Beta 1.72
  • Price/Sales 1.03
  • Price/Cash Flow N/A
  • Price/Book 3.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.64
  • Number of Estimates 2
  • High Estimate -1.56
  • Low Estimate -1.72
  • Prior Year -1.10
  • Growth Rate Est. (year over year) -49.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.51 +38.58%
on 07/14/20
8.32 -24.88%
on 07/24/20
+0.11 (+1.79%)
since 07/02/20
3-Month
4.31 +45.01%
on 07/01/20
8.32 -24.88%
on 07/24/20
+1.05 (+20.19%)
since 05/05/20
52-Week
3.81 +64.04%
on 11/26/19
11.00 -43.18%
on 02/21/20
-2.18 (-25.86%)
since 08/05/19

Most Recent Stories

More News
Life Sciences Heavyweight, Dr Joe Keegan, Joins Fast Growing Nuclera's Board as Non-executive Director

Nuclera, a Cambridge, UK-based biotech company developing benchtop gene and protein printing technologies, is pleased to announce that Dr Joe Keegan has been appointed to its Board as Non-executive Director....

PLL : 6.53 (+1.24%)
TECH : 270.78 (-2.21%)
IDXG : 6.24 (-2.50%)
Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays

Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting

IDXG : 6.24 (-2.50%)
Interpace Biosciences Announces First Quarter 2020 Financial and Business Results

First Quarter Net Revenue Improved Over 53% to $9.2 Million

IDXG : 6.24 (-2.50%)
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020

Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m. ET. Interpace will host a conference call and webcast...

IDXG : 6.24 (-2.50%)
Interpace Biosciences Announces Contract with Lab Benefits Management Firm

In-Network Access for More Than 3 Million Members

IDXG : 6.24 (-2.50%)
Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results

Conference Call and Webcast Wednesday April 22, 2020 5:00 pm ET

IDXG : 6.24 (-2.50%)
Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial Results on Wednesday, April 22, 2020

Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company management will host a conference call and webcast to discuss...

IDXG : 6.24 (-2.50%)
Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts

Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts. While terms of this Agreement...

IDXG : 6.24 (-2.50%)
Interpace Diagnostics Announces Contract with BCBS of Massachusetts

In-Network Access for More Than 3 Million Members

IDXG : 6.24 (-2.50%)
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company's ThyGeNEXT and ThyraMIR tests in the Journal of the American...

IDXG : 6.24 (-2.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade IDXG with:

Business Summary

Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey.

See More

Key Turning Points

2nd Resistance Point 6.78
1st Resistance Point 6.59
Last Price 6.24
1st Support Level 6.09
2nd Support Level 5.79

See More

52-Week High 11.00
Fibonacci 61.8% 8.25
Fibonacci 50% 7.41
Fibonacci 38.2% 6.56
Last Price 6.24
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar